Bristol Myers Squibb (BMY) announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.These data include long-term data with three-year follow-up from the late-stage TRANSFORM study of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL). These also include results from a subgroup analysis evaluating the efficacy and safety of Breyanzi by a number ...

Bristol Myers Squibb (BMY) announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.These data include long-term data with three-year follow-up from the late-stage TRANSFORM study of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL). These also include results from a subgroup analysis evaluating the efficacy and safety of Breyanzi by a number ...

PM Images I am not a trader, and I make most of my investment decisions based on a long-term time horizon. I can't time the market, and Bristol-Myers Squibb (NYSE:BMY) is a perfect example of an investment that's continued lower despite my long-term investment thesis. BMY looks like a falling knife, and the cuts are getting deeper and deeper. Over the past year, shares of BMY have declined by -36.24% as they fell from the mid $60s to the low $40s. Nothing about the long-term charts is exciting either, as BM ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $41.77, denoting a +1.65% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.11%. Meanwhile, the Dow experienced a drop of 0.3%, and the technology-dominated Nasdaq saw an increase of 0.56%.The the stock of biopharmaceutical company has fallen by 6.59% in the past month, lagging the Medical sector's gain of 2.86% and the S&P 500's gain of 5.06%.Investors will be eagerly watching for the performance of Bri ...

MarsBars A recent article highlighted keys to success for Amazon (AMZN) CEO, Andy Jassy, in which he attributed the following points to an 'embarrassing' amount of success. Specifically, he remarked on the following points in which a career professional should be able to confidently answer 'yes' to: Do you work hard? Are you more can-do than naysaying? Do you do what you said you were going to do? Can you work in a team? These are all admirable traits and while they don’t translate in the same to succ ...

This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come.Searching for investments that can outperform the benchmark S&P 500 index often gets wickedly complicated. If you're new to the investing process, you'll be glad to learn that building a portfolio that can outperform the broad market isn't as difficult as it seems.Filling your portfolio with top dividend-paying stocks doesn't guarantee great returns, but you'd have to be unlucky to underpe ...

Trevor Williams The first-quarter earnings season is largely in the books. S&P 500 operating EPS growth was solid at 6.4%. Critics contend that if you back out the very impressive profits from the Magnificent 7 stocks, then the market’s earnings growth rate is less sublime. I counter that argument with the reality that, if you also remove the roughly $13 billion of total acquisition and transaction costs related to several deals closed in the first quarter by Bristol-Myers Squibb Company (NYSE:BMY), th ...

Bristol Myers Squibb (BMY) announced that the European Commission (EC) has approved its blockbuster immuno-oncology drug, Opdivo (nivolumab), in combination with a chemotherapy combination, cisplatin and gemcitabine, as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma (UC).Following the approval in Europe, the Opdivo combination became the first concurrent immunotherapy-chemotherapy approved for treating adult patients with unresectable or metastatic UC in a fir ...

Forbes Community GuidelinesOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.In order to do so, please follow the posting rules in our site's Terms of Service.  We've summarized some of those key rules below. Simply put, keep it civil.Your post will be rejected if we notice that it seems to contain:False or intentionally out-of-context or misleading informationSpamInsults, profanity, incoh ...

In this articleAZN-GBBMYLLYNVSNOV.N-CHSkynesher | E+ | Getty ImagesBig pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a "massive opportunity."It's called targeted radiopharmaceuticals. The therapy essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.RBC Capital Markets sees a $25 billion market opportunity for the space."We believe TRT development is still in its early stages, and next- ...